




PHARMACEUTICAL 2023

Vincerx Pharma Inc.
Rank 256 of 446





RealRate

PHARMACEUTICAL 2023

Vincerx Pharma Inc.
Rank 256 of 446



The relative strengths and weaknesses of Vincerx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vincerx Pharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Vincerx Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 3.7% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	55,964
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,156
Liabilities, Non-Current	2,462
Other Assets	3,145
Other Compr. Net Income	-5.0
Other Expenses	2,469
Other Liabilities	0
Other Net Income	8,207
Other Revenues	0
Property and Equipment	177
Research and Development	52,152
Selling, General and Administrative Expense	18,953

Output Variable	Value in 1000 USD
Assets	59,286
Liabilities	11,618
Expenses	73,574
Revenues	0
Stockholders Equity	47,668
Net Income	-65,367
Comprehensive Net Income	-65,370
Economic Capital Ratio	47%